Recommendations for Probiotic Use-2011 Update

Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT 06150, USA.
Journal of clinical gastroenterology (Impact Factor: 3.19). 11/2011; 45 Suppl:S168-71. DOI: 10.1097/MCG.0b013e318230928b
Source: PubMed

ABSTRACT This study describes the consensus opinion of the participants of the third Yale Workshop on probiotic use. There were 10 experts participating. The recommendations update those of the first 2 meetings that were published in 2005 and 2008. The workshop presentations and papers in this supplement relate to the involvement of normal microbiota involved in intestinal microecology, how the microbes interact with the intestine to affect our immunologic responses, the stability and natural history of probiotic organisms, and the role of the intestinal microbatome with regard to affecting cardiac risk factors and obesity. Recommendations for the use of probiotics in necrotizing enterocolitis, childhood diarrhea, inflammatory bowel disease, irritable bowel syndrome, and Clostridium difficile diarrhea are reviewed. As in previous publications, the recommendations are given as A, B, or C ratings. The recent positive experiences with bacteriotherapy (fecal microbiome transplant) are also discussed in detail and a positive recommendation is made for use in severe resistant C. difficile diarrhea.


Available from: Levinus A Dieleman, Jun 09, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: The incidence of nosocomial infections in children in developed countries is still high, ranging from 8% to 30%, and standard preventive measures, such as increased hygiene, are not sufficiently efficacious. One of the potential strategies for their prevention is the use of probiotics. The aim of the study was to investigate the role of Bifidobacterium animalis subsp. lactis in preventing nosocomial infections in the acute hospital setting. We conducted a randomized, double-blind, placebo-controlled trial in 727 hospitalized children (aged 1-18 y). The children were randomly allocated to receive placebo (placebo group, n = 365) or B. animalis subsp. lactis at a dose of 10(9) colony-forming units/d (intervention group, n = 362) once daily for the entire duration of the hospital stay. Nosocomial infections were defined as infections that occurred >48 h after hospital admission and that were not present or incubating at the time of admission. Analysis was performed on an intention-to-treat basis. There was no difference in the study primary outcome or incidence of common nosocomial gastrointestinal and respiratory tract infections between groups (22 vs. 29 infections, respectively; incidence rate ratio = 0.76; 95% CI: 0.41, 1.36; P = 0.32). No difference was found for the duration of common nosocomial infections [mean (range): 3.58 (1-7) vs. 3.79 (1-8) d, in placebo vs. intervention group; P = 0.74]. There was also no difference between the intervention and placebo groups for any of the other secondary outcomes (incidence of gastrointestinal and respiratory tract infections separately, duration of gastrointestinal and respiratory infections, and duration of hospitalization) and exploratory outcomes (gastrointestinal and respiratory symptoms, severity of gastrointestinal and respiratory tract infections, and the use of antibiotics). The results of this study show that the use of B. animalis subsp. lactis failed to prevent nosocomial infections in an acute-setting pediatric hospital in children who were >1 y of age. However, it should be taken into account that the overall incidence of nosocomial infections was lower than expected. This trial was registered at as NCT01702766. © 2015 American Society for Nutrition.
    American Journal of Clinical Nutrition 03/2015; 101(3):680-4. DOI:10.3945/ajcn.114.102004 · 6.92 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The colonisation and establishment of the intestinal microbiota starts immediately at birth and is essential for the development of the intestine and the immune system. This microbial community gradually increases in number and diversity until the age of two or three years when it becomes a stable ecosystem resembling that of adults. This period constitutes a unique window of opportunity to modulate it through probiotic action, with a potential impact in later health. In the present work we have investigated how putative bifidobacterial probiotics modify the metabolic profiles and immune-modulatory properties of faecal microbiotas. An in vitro pH-controlled single-stage continuous-culture system (CCS) inoculated with infant faeces was employed to characterise the effects of two Bifidobacterium species on the intestinal microbiotas in three children, together with the effects of these modified microbiotas on cytokine production by HT-29 cells. Intestinal bacterial communities, production of short-chain fatty acids and lactate were determined by quantitative PCR and gas chromatography, respectively. Cytokines production by HT-29 cells was measured by ELISA. The combination of CCS with infant faeces and human intestinal cells provided a suitable model to evaluate the specific modulation of the intestinal microbiota and immune system by probiotics. In the CCS, infant faecal microbiotas were influenced by the addition of bifidobacteria, resulting in changes in their ability to induce the production of immune mediators by HT-29 cells. The different metabolic and immunological responses induced by the bifidobacterial species tested indicate the need to assess potential probiotics in model systems including complex intestinal microbiotas. Potential probiotic bifidobacteria can modulate the infant microbiota and its ability to induce the production of mediators of the immune response by intestinal cells.
    Beneficial Microbes 02/2015; 1(-1):1-10. DOI:10.3920/BM2014.0111 · 1.50 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Barrett's oesophagus (BO) is a complicated condition at gastroesophageal junction in which normal squamous epithelium is changed to columnar and leads to oesophageal adenocarcinoma (OA). In the past decades, prevalence of Barrett's disease and mortality rate of adenocarcinoma has significantly increased through the word. Data represent that molecular pathogenesis of disease has not been clearly identified. However, wide range and successful administration of probiotics in cancer and gastrointestinal diseases lead to create the idea of investigation possible inhibitory role of probiotics to inhibit oesophageal cancer. This study was conducted to evaluate the inhibition effect of probiotics on the expression of biomarkers in in vitro model. Two different Barrett's oesophageal cell lines were selected to co-culture with Bifidobacterium longum and Lactobacillus acidophilus to measure expression of IL18 (interleukin 18), TNFα (tumour necrosis factor-α), p53 (tumour suppressor gene), COX2 (cyclooxygenase 2), and CDX1 (caudal type homeobox 1) genes. In addition, two different aspects of probiotic administration, therapeutic and prophylactic test was also examined. Results showed that microorganisms could inhibit expression of biomarkers, and therapeutic culture condition was more effective than prophylactic test. Obtained results suggest that it is possibility to apply administration of probiotics in BO and OA prevention.
    Journal of Medical Microbiology 02/2015; 64(Pt_4). DOI:10.1099/jmm.0.000039 · 2.27 Impact Factor